Patritumab (Anti-ERBB3 / HER3)
Product Specifications
CAS Number
1262787-83-6
Synonyms
Human Anti-ERBB3 Recombinant Antibody
Target
HER2
Applications
Protein Tyrosine Kinase
Additionnal Information
Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040031-500 1x 500 µL
Mucin 5AC (MUC5AC) (45M1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470841-500 1x 500 µL
Pgp9.5 (UCHL-1) (UCHL1/841), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC740521-100 1x 100 µL
AFP (Alpha Fetoprotein) (MBS-12), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details